Cargando…

Leveraging the Variability of Pharmacovigilance Disproportionality Analyses to Improve Signal Detection Performances

Background: A plethora of methods and models of disproportionality analyses for safety surveillance have been developed to date without consensus nor a gold standard, leading to methodological heterogeneity and substantial variability in results. We hypothesized that this variability is inversely co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khouri, Charles, Nguyen, Thuy, Revol, Bruno, Lepelley, Marion, Pariente, Antoine, Roustit, Matthieu, Cracowski, Jean-Luc
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8193489/ https://www.ncbi.nlm.nih.gov/pubmed/34122089 http://dx.doi.org/10.3389/fphar.2021.668765

Ejemplares similares

Identifying new drugs associated with pulmonary arterial hypertension: A WHO pharmacovigilance database disproportionality analysis
por: Hlavaty, Alex, et al.
Publicado: (2022)

Adverse event reporting and Bell's palsy risk after COVID-19 vaccination
por: Khouri, Charles, et al.
Publicado: (2021)

Impact of global warming on Raynaud’s phenomenon: a modelling study
por: Khouri, Charles, et al.
Publicado: (2020)

Editorial: Leveraging pharmacovigilance data mining with “the patient” in mind
por: Gossell-Williams, Maxine, et al.
Publicado: (2022)

Safety profile of vascular endothelial growth factor receptor tyrosine-kinase inhibitors in pediatrics: a pharmacovigilance disproportionality analysis
por: Xue, Yifei, et al.
Publicado: (2023)

Association between NMDAR antagonists, drug abuse and dependence: A disproportionality analysis from the WHO pharmacovigilance database
por: Revol, Bruno, et al.
Publicado: (2022)

Mapping Strategies to Assess and Increase the Validity of Published Disproportionality Signals: A Meta-Research Study
por: Fusaroli, Michele, et al.
Publicado: (2023)

Neurological Adverse Events Associated With Esketamine: A Disproportionality Analysis for Signal Detection Leveraging the FDA Adverse Event Reporting System
por: Guo, Haoning, et al.
Publicado: (2022)

COVID-19 et vaccins à adénovirus : expérience française de suivi renforcé de pharmacovigilance
por: Massy, Nathalie, et al.
Publicado: (2023)

Corrigendum: Neurological adverse events associated with esketamine: A disproportionality analysis for signal detection leveraging the FDA adverse event reporting system
por: Guo, Haoning, et al.
Publicado: (2022)

Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database
por: Liu, Wensheng, et al.
Publicado: (2023)

Propensity Score-Based Approaches in High Dimension for Pharmacovigilance Signal Detection: an Empirical Comparison on the French Spontaneous Reporting Database
por: Courtois, Émeline, et al.
Publicado: (2018)

Spontaneous Reports of Serious Adverse Drug Reactions Resulting From Drug–Drug Interactions: An Analysis From the French Pharmacovigilance Database
por: Létinier, Louis, et al.
Publicado: (2021)

Application of Pharmacovigilance Methods in Occupational Health Surveillance: Comparison of Seven Disproportionality Metrics
por: Bonneterre, Vincent, et al.
Publicado: (2012)

A real-world disproportionality analysis of Rucaparib: Post-marketing Pharmacovigilance Data
por: Zhang, Qilin, et al.
Publicado: (2023)

Anti-NMDA receptor encephalitis and vaccination: A disproportionality analysis
por: Martin, Salomé, et al.
Publicado: (2022)

Understanding the variability of pharmaco‐epidemiological studies assessing the risk of appendicitis with mRNA COVID‐19 vaccines
por: Jambon‐Barbara, Clement, et al.
Publicado: (2022)

COVID-19 Vaccine-Associated Transient Global Amnesia: A Disproportionality Analysis of the WHO Safety Database
por: Merino, Diane, et al.
Publicado: (2022)

Infections associated with clozapine: a pharmacovigilance study using VigiBase(®)
por: Chrétien, Basile, et al.
Publicado: (2023)

Safety Profile of Ibrutinib: An Analysis of the WHO Pharmacovigilance Database
por: Allouchery, Marion, et al.
Publicado: (2021)

Ototoxic Adverse Drug Reactions: A Disproportionality Analysis Using the Italian Spontaneous Reporting Database
por: Barbieri, Maria Antonietta, et al.
Publicado: (2019)

Disproportionality Analysis for Pharmacovigilance Signal Detection in Small Databases or Subsets: Recommendations for Limiting False-Positive Associations
por: Caster, Ola, et al.
Publicado: (2020)

Is Omalizumab Related to Ear and Labyrinth Disorders? A Disproportionality Analysis Based on a Global Pharmacovigilance Database
por: Park, Hyeon Tae, et al.
Publicado: (2022)

An update on the Pharmacovigilance Programme of India
por: Lihite, Ratan J., et al.
Publicado: (2015)

Pharmacovigilance on cannabidiol as an antiepileptic agent
por: Ammendolia, Ilaria, et al.
Publicado: (2023)

Post-Marketing Safety Concerns With Secukinumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System
por: Shu, Yamin, et al.
Publicado: (2022)

A real-world disproportionality analysis of apalutamide: data mining of the FDA adverse event reporting system
por: Fang, Zhihong, et al.
Publicado: (2023)

Proarrhythmia associated with antiarrhythmic drugs: a comprehensive disproportionality analysis of the FDA adverse event reporting system
por: Wang, Feifei, et al.
Publicado: (2023)

Suspected Adverse Drug Reactions Related to Breast Cancer Chemotherapy: Disproportionality Analysis of the Brazilian Spontaneous Reporting System
por: Barcelos, Flávia Campos, et al.
Publicado: (2019)

Acute Kidney Injury and Drugs Prescribed for COVID-19 in Diabetes Patients: A Real-World Disproportionality Analysis
por: Zhou, Yu, et al.
Publicado: (2022)

Thromboembolism and Oral Contraceptives During the COVID-19 Pandemic: A Disproportionality Analysis Within the Spanish Pharmacovigilance Database
por: Martín, Luis H., et al.
Publicado: (2022)

Cardiac arrhythmias associated with immune checkpoint inhibitors: A comprehensive disproportionality analysis of the FDA adverse event reporting system
por: Wang, Feifei, et al.
Publicado: (2022)

Immunohistochemical, pharmacovigilance, and omics analyses reveal the involvement of ATP-sensitive K(+) channel subunits in cancers: role in drug–disease interactions
por: Maqoud, Fatima, et al.
Publicado: (2023)

Adverse events associated with molnupiravir: a real-world disproportionality analysis in food and drug administration adverse event reporting system
por: Liang, Yankun, et al.
Publicado: (2023)

Editorial: Reducing the Harm of Medication–Recent Trends in Pharmacovigilance
por: Ramírez, Elena, et al.
Publicado: (2022)

Expert consensus on neurodevelopmental outcomes in pregnancy pharmacovigilance studies
por: Bromley, R. L., et al.
Publicado: (2023)

Editorial: Pharmacovigilance and drug repositioning research using pharmacoepidemiology
por: Noguchi, Yoshihiro, et al.
Publicado: (2023)

Mining Patients' Narratives in Social Media for Pharmacovigilance: Adverse Effects and Misuse of Methylphenidate
por: Chen, Xiaoyi, et al.
Publicado: (2018)

The Role of an Interventional Program for Improving Pharmacovigilance at a Pediatric Facility
por: Kronenfeld, Nirit, et al.
Publicado: (2019)

Safety of Inulin and Sinistrin: Combining Several Sources for Pharmacovigilance Purposes
por: Bui, T-V., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_q7s2unp2apnl25ik3tubp8kj0v